24/7 Market News Snapshot 18 December, 2024 – Mesoblast Limited American Depositary Shares (NASDAQ:MESO)

December 18, 2024

DENVER, Colo., 18 December, 2024 (247marketnews.com) – (NASDAQ:MESO) are discussed in this article.
Shares of Mesoblast Limited (NASDAQ:MESO) have seen a significant surge today, reflecting robust investor confidence. Opening at $13.10, the stock has skyrocketed by over 26% to reach a current value of $15.834, driven by a trading volume of approximately 687.61K shares. This noteworthy increase underscores the company’s promising trajectory in the biotechnology sector, capturing heightened interest among investors.

In a separate but related development, Mesoblast has been announced for inclusion in the prestigious Nasdaq Biotechnology Index, effective December 23, 2024. This milestone is a significant acknowledgment of the company’s growth and its innovations in allogeneic cellular medicines designed to treat severe inflammatory diseases. Being part of this elite index, which features a select group of Nasdaq-listed biotech firms, emphasizes Mesoblast’s strong market position and commitment to advancing healthcare.

Mesoblast utilizes its proprietary mesenchymal lineage cell therapy technology to develop off-the-shelf cellular medicines. The company is focused on addressing critical medical challenges, including steroid-refractory acute graft versus host disease and advanced chronic heart failure, with its late-stage product candidates leveraging the innovative remestemcel-L and rexlemestrocel-L platforms.

With established commercial partnerships in key global markets, Mesoblast is poised to expand the accessibility of its groundbreaking therapies. The company boasts an extensive intellectual property portfolio, securing its innovations until at least 2041, which reinforces its competitive edge in the industry.

As Mesoblast positions itself within the Nasdaq Biotechnology Index and continues to enhance its clinical endeavors, it remains dedicated to transforming treatment outcomes for patients suffering from severe inflammatory diseases, demonstrating its commitment to medical excellence and innovation.

Related news for (MESO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.